Earendil Labs said on September 24 it will lead discovery through early clinical development of multiple oncology bispecific antibodies for Genentech, which then takes global development and commercialization. Earendil gets $55 million upfront and is eligible for development, regulatory and sales milestones that could take the collaboration above $1.5 billion, plus tiered royalties; the deal is subject to customary closing and does not name the target combinations. Fierce Biotech reported the same economics on September 25 and confirmed the programs remain undisclosed.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.